This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (60)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Lipids and Lipid Disorders  • Alert me on articles by topic

Hannia Campos, PhD; Lemuel A. Moye, MD; Stephen P. Glasser, MD; Meir J. Stampfer, MD,DPH; Frank M. Sacks, MD

JAMA. 2001;286:1468-1474.

Context  Small low-density lipoprotein (LDL) particle size has been hypothesized to be a risk factor for coronary heart disease (CHD). Animal models link large LDL to atherosclerosis. However, the strong association between small LDL and other risk factors, particularly triglyceride levels, impedes determining whether LDL size independently predicts CHD in humans.

Objective  To examine whether LDL size is an independent predictor of recurrent coronary events in patients with known CHD, as opposed to a marker for other lipid abnormalities.

Design and Setting  Prospective, nested case-control study in the Cholesterol and Recurrent Events (CARE) trial, a randomized placebo-controlled trial of pravastatin conducted in 1989-1996.

Participants  Survivors of myocardial infarction with typical LDL concentrations (416 cases and 421 controls).

Main Outcome Measure  Subsequent myocardial infarction or coronary death during the 5-year follow-up, analyzed by quintile of LDL particle size and by treatment group.

Results  Overall, the mean LDL size was identical in cases and controls (25.6 nm). In patients in the placebo group, large LDL predicted coronary events in models adjusted only for age (relative risk [RR], 1.79; 95% confidence interval [CI], 1.01-3.17) and for age and lipid and nonlipid risk factors (RR, 4.00; 95% CI, 1.81-8.82), comparing those in the highest (mean, 26.6 nm) and lowest (mean, 24.5 nm) quintiles of LDL size. This increased risk was not present in those taking pravastatin (age-adjusted analysis: RR, 0.98; 95% CI, 0.47-2.04; P = .046 for interaction for a difference in the effect of LDL size on coronary events between the placebo and treatment groups; multivariable analysis: RR, 1.33; 95% CI, 0.52-3.38; P = .11 for interaction).

Conclusions  Large LDL size was an independent predictor of coronary events in a typical population with myocardial infarction, but the adverse effect was not present among patients who were treated with pravastatin. Identifying patients on the basis of LDL size may not be useful clinically, since effective treatment for elevated LDL cholesterol concentrations also effectively treats risk associated with large LDL.

Author Affiliations: Department of Nutrition, Harvard School of Public Health (Drs Campos and Sacks); Department of Medicine, Harvard Medical School (Drs Stampfer and Sacks); and Brigham and Women's Hospital (Dr Sacks), Boston, Mass; University of Texas School of Public Health, Houston (Dr Moye); and Division of Epidemiology, University of Minnesota, Minneapolis-St Paul (Dr Glasser).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Insulin Resistance, Dyslipidemia, and Cardiovascular Disease
Bloomgarden
Diabetes Care 2007;30:2164-2170.
FULL TEXT  

Low-density lipoprotein size and cardiovascular risk assessment
Rizzo and Berneis
QJM 2006;99:1-14.
ABSTRACT | FULL TEXT  

Dietary and Genetic Probes of Atherogenic Dyslipidemia
Krauss
Arterioscler. Thromb. Vasc. Bio. 2005;25:2265-2272.
ABSTRACT | FULL TEXT  

ACAT2 Is a Target for Treatment of Coronary Heart Disease Associated With Hypercholesterolemia
Rudel et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1112-1118.
ABSTRACT | FULL TEXT  

Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Quebec Cardiovascular Study
St-Pierre et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:553-559.
ABSTRACT | FULL TEXT  

Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study
Marz et al.
Circulation 2004;110:3068-3074.
ABSTRACT | FULL TEXT  

Arterial Permeability and Efflux of Apolipoprotein B-Containing Lipoproteins Assessed by In Situ Perfusion and Three-Dimensional Quantitative Confocal Microscopy
Proctor et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:2162-2167.
ABSTRACT | FULL TEXT  

In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis
Geiss et al.
J. Lipid Res. 2004;45:1459-1467.
ABSTRACT | FULL TEXT  

Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations
Bosse et al.
J. Lipid Res. 2004;45:1008-1026.
ABSTRACT | FULL TEXT  

Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
Sacks and Campos
J. Clin. Endocrinol. Metab. 2003;88:4525-4532.
FULL TEXT  

Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study
Winkler et al.
Diabetes Care 2003;26:2588-2594.
ABSTRACT | FULL TEXT  

LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients
Lee et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:853-858.
ABSTRACT | FULL TEXT  

Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS)
Vakkilainen et al.
Circulation 2003;107:1733-1737.
ABSTRACT | FULL TEXT  

Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in Men
Williams et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:314-321.
ABSTRACT | FULL TEXT  

Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action
Winkler et al.
J. Clin. Endocrinol. Metab. 2002;87:5485-5490.
ABSTRACT | FULL TEXT  

Coronary atherogenic risk factors in women
Stangl et al.
Eur Heart J 2002;23:1738-1752.
FULL TEXT  

New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg
Circulation 2002;106:2137-2142.
FULL TEXT  

Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women
Blake et al.
Circulation 2002;106:1930-1937.
ABSTRACT | FULL TEXT  

Metabolic origins and clinical significance of LDL heterogeneity
Berneis and Krauss
J. Lipid Res. 2002;43:1363-1379.
ABSTRACT | FULL TEXT  

Dietary Mono- and Polyunsaturated Fatty Acids Similarly Affect LDL Size in Healthy Men and Women
Kratz et al.
J. Nutr. 2002;132:715-718.
ABSTRACT | FULL TEXT  

In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice
Furbee et al.
J. Lipid Res. 2002;43:428-437.
ABSTRACT | FULL TEXT  

Is the Size of Low-Density Lipoprotein Particles Related to the Risk of Coronary Heart Disease?
Krauss et al.
JAMA 2002;287:712-713.
FULL TEXT  

Diffusion of Nitric Oxide into Low Density Lipoprotein
Denicola et al.
J. Biol. Chem. 2002;277:932-936.
ABSTRACT | FULL TEXT